Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2017

11.04.2017

Pulmonary embolism response teams

verfasst von: Maya Serhal, Ihab S. Haddadin, Gustavo A. Heresi, Deborah A. Hornacek, Mehdi H. Shishehbor, John R. Bartholomew

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Pulmonary embolism (PE) is a common thrombotic event that is variable in its presentation. Depending on the patients’ risk for mortality, guidelines provide several treatment strategies including thrombolysis, catheter-directed therapies, pulmonary embolectomy, anticoagulation, and inferior vena cava filters. However, there is considerable disagreement between guidelines regarding the optimal treatment strategy for patients, particularly for those with intermediate-risk PE. In order to provide rapid and individualized care, PE response teams (PERT) have been developed. These teams consist of members from different specialties with a particular interest in PE, varying technical skills, and clinical experience, thereby allowing for a multidisciplinary approach. PERT allows for consensus decision making, and for rapid intervention in patients whose conditions worsen. In this review, we provide an overview of treatment guidelines for PE, and of results from recent clinical trials involving patients with submassive PE. In addition, we discuss an outline of our approach and use of PERT.
Literatur
1.
Zurück zum Zitat Beckman MG, Hooper WC, Critchley SE, Ortel TL (2010) Venous thromboembolism: a public health concern. Am J Prev Med 38:S495–S501CrossRefPubMed Beckman MG, Hooper WC, Critchley SE, Ortel TL (2010) Venous thromboembolism: a public health concern. Am J Prev Med 38:S495–S501CrossRefPubMed
2.
Zurück zum Zitat Fanikos J, Rao A, Seger AC, Carter D, Piazza G, Goldhaber SZ (2013) Hospital costs of acute pulmonary embolism. Am J Med 126:127–132CrossRefPubMed Fanikos J, Rao A, Seger AC, Carter D, Piazza G, Goldhaber SZ (2013) Hospital costs of acute pulmonary embolism. Am J Med 126:127–132CrossRefPubMed
3.
Zurück zum Zitat Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:315–352CrossRefPubMed Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:315–352CrossRefPubMed
4.
Zurück zum Zitat Jaff MR, McMurtry MS, Archer SL et al (2011) Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 123:1788–1830CrossRefPubMed Jaff MR, McMurtry MS, Archer SL et al (2011) Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 123:1788–1830CrossRefPubMed
5.
Zurück zum Zitat Konstantinides SV, Torbicki A, Agnelli G et al. (2014) 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35:3033–3069, 69a-69k Konstantinides SV, Torbicki A, Agnelli G et al. (2014) 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35:3033–3069, 69a-69k
6.
Zurück zum Zitat Aujesky D, Obrosky DS, Stone RA et al (2005) Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 172:1041–1046CrossRefPubMedPubMedCentral Aujesky D, Obrosky DS, Stone RA et al (2005) Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 172:1041–1046CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Venetz C, Jimenez D, Mean M, Aujesky D (2011) A comparison of the original and simplified pulmonary embolism severity index. Thromb Haemost 106:423–428CrossRefPubMed Venetz C, Jimenez D, Mean M, Aujesky D (2011) A comparison of the original and simplified pulmonary embolism severity index. Thromb Haemost 106:423–428CrossRefPubMed
8.
Zurück zum Zitat Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e419S–e494SCrossRefPubMedPubMedCentral Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e419S–e494SCrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Konstantinides S, Geibel A, Heusel G et al (2002) Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 347:1143–1150CrossRefPubMed Konstantinides S, Geibel A, Heusel G et al (2002) Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 347:1143–1150CrossRefPubMed
10.
Zurück zum Zitat Meyer G, Vicaut E, Danays T et al (2014) Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 370:1402–1411CrossRefPubMed Meyer G, Vicaut E, Danays T et al (2014) Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 370:1402–1411CrossRefPubMed
11.
Zurück zum Zitat Kline JA, Nordenholz KE, Courtney DM et al (2014) Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost 12:459–468CrossRefPubMed Kline JA, Nordenholz KE, Courtney DM et al (2014) Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost 12:459–468CrossRefPubMed
12.
Zurück zum Zitat Wang C, Zhai Z, Yang Y et al (2010) Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 137:254–262CrossRefPubMed Wang C, Zhai Z, Yang Y et al (2010) Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 137:254–262CrossRefPubMed
13.
Zurück zum Zitat Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M, Investigators M (2013) Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” trial). Am J Cardiol 111:273–277CrossRefPubMed Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M, Investigators M (2013) Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” trial). Am J Cardiol 111:273–277CrossRefPubMed
14.
Zurück zum Zitat Kucher N, Boekstegers P, Muller OJ et al (2014) Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 129:479–486CrossRefPubMed Kucher N, Boekstegers P, Muller OJ et al (2014) Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 129:479–486CrossRefPubMed
15.
Zurück zum Zitat Piazza G, Hohlfelder B, Jaff MR et al (2015) A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study. JACC Cardiovasc Interv 8:1382–1392CrossRefPubMed Piazza G, Hohlfelder B, Jaff MR et al (2015) A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study. JACC Cardiovasc Interv 8:1382–1392CrossRefPubMed
16.
17.
Zurück zum Zitat PRADAXA® (dabigatran etexilate mesylate) capsules for oral use. Full Prescribing Information. Boehringer Ingelheim Pharmaceuticals, Inc 2015 PRADAXA® (dabigatran etexilate mesylate) capsules for oral use. Full Prescribing Information. Boehringer Ingelheim Pharmaceuticals, Inc 2015
18.
Zurück zum Zitat XARELTO® (rivaroxaban) tablets, for oral use. Full prescribing information. Janssen Pharmaceutical, Inc 2016 XARELTO® (rivaroxaban) tablets, for oral use. Full prescribing information. Janssen Pharmaceutical, Inc 2016
19.
Zurück zum Zitat Brekelmans MP, Ageno W, Beenen LF et al. (2016) Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol 3:e437–e445CrossRefPubMed Brekelmans MP, Ageno W, Beenen LF et al. (2016) Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol 3:e437–e445CrossRefPubMed
20.
Zurück zum Zitat SAVAYSA® (edoxaban) tablets for oral use. Full prescribing information. Daiichi Sankyo, Inc 2016 SAVAYSA® (edoxaban) tablets for oral use. Full prescribing information. Daiichi Sankyo, Inc 2016
21.
Zurück zum Zitat Schulman S, Kakkar AK, Goldhaber SZ et al (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129:764–772CrossRefPubMed Schulman S, Kakkar AK, Goldhaber SZ et al (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129:764–772CrossRefPubMed
22.
Zurück zum Zitat Einstein-PE Investigators, Buller HR, Prins MH et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297CrossRef Einstein-PE Investigators, Buller HR, Prins MH et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297CrossRef
23.
Zurück zum Zitat Einstein Investigators, Bauersachs R, Berkowitz SD et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510CrossRef Einstein Investigators, Bauersachs R, Berkowitz SD et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510CrossRef
24.
Zurück zum Zitat Hokusai VTE Investigators, Buller HR, Decousus H et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406–1415CrossRef Hokusai VTE Investigators, Buller HR, Decousus H et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406–1415CrossRef
25.
Zurück zum Zitat Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352CrossRefPubMed Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352CrossRefPubMed
26.
Zurück zum Zitat Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808CrossRefPubMed Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808CrossRefPubMed
27.
Zurück zum Zitat Sharifi M, Vajo Z, Freeman W, Bay C, Sharifi M, Schwartz F (2015) Transforming and simplifying the treatment of pulmonary embolism: “safe dose” thrombolysis plus new oral anticoagulants. Lung 193:369–374CrossRefPubMed Sharifi M, Vajo Z, Freeman W, Bay C, Sharifi M, Schwartz F (2015) Transforming and simplifying the treatment of pulmonary embolism: “safe dose” thrombolysis plus new oral anticoagulants. Lung 193:369–374CrossRefPubMed
Metadaten
Titel
Pulmonary embolism response teams
verfasst von
Maya Serhal
Ihab S. Haddadin
Gustavo A. Heresi
Deborah A. Hornacek
Mehdi H. Shishehbor
John R. Bartholomew
Publikationsdatum
11.04.2017
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2017
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-017-1498-9

Weitere Artikel der Ausgabe 1/2017

Journal of Thrombosis and Thrombolysis 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.